Short answer
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA-approved ASCENIV label expansion for immune-compromised pediatric patients aged 2 and older.
ADMA BIOLOGICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA-approved ASCENIV label expansion for immune-compromised pediatric patients aged 2 and older
- Expanded indication increases eligible patient population and commercial reach
- Regulatory milestone may support ASCENIV growth and strengthen ADMA’s plasma-derived immunoglobulin portfolio
- Press release dated May 4, 2026 provides additional details
Item EX-99.1 · Exhibit EX-99.1
- FDA expanded ASCENIV’s PI indication to immune-compromised pediatric patients aged 2 years and older, versus 12 years previously
- Approval fulfills ADMA’s post-marketing pediatric assessment commitment and supports broader commercial utilization
- Expanded label opens access to younger patients within ASCENIV’s existing primary humoral immunodeficiency market
- ASCENIV remains a 10% plasma-derived IVIG product with thrombosis, renal dysfunction, and hypersensitivity warnings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADMA BIOLOGICS, INC. 8-K filings
Get the next ADMA 8-K as it lands
Follow ADMA for push alerts, or ask the research agent what this filing means.